Movement Alert|Teva Pharmaceutical Falls 4.19% in Regular Trading, R&D Chief Departure Weighs on Sentiment

Market Focus11-19 23:07

On November 19, Teva Pharmaceutical fell 4.19% in Regular Trading, trading at $40.485/share, with turnover of $52.3944 million.

The move followed the company’s announcement that Chief Medical Officer and Executive Vice President of Global Research and Development Eric Hughes is departing after accepting a position outside the company, prompting a leadership transition in a key innovation role.

Teva said Hughes will remain through the coming months to support the transition, while David Gardiner, head of innovative medicines and clinical development, will serve as R&D transition lead until a permanent successor is appointed. The company added that strategy, R&D priorities and expectations remain unchanged and that a search for a successor is underway. The reaction came shortly after Teva’s recent R&D day and innovation updates, making the management change a focal point for investors despite recent analyst price-target increases and the FDA approval of at-home use for Igalmi.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment